Compare UP & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UP | SNDX |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | 1250 | 298 |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.3M | 1.8B |
| IPO Year | N/A | 2014 |
| Metric | UP | SNDX |
|---|---|---|
| Price | $8.81 | $19.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $38.69 |
| AVG Volume (30 Days) | 238.2K | ★ 1.5M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | N/A | $107.19 |
| Revenue Next Year | N/A | $41.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $0.36 | $8.59 |
| 52 Week High | $9.70 | $25.59 |
| Indicator | UP | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 71.14 | 41.06 |
| Support Level | $0.79 | $19.28 |
| Resistance Level | N/A | $22.40 |
| Average True Range (ATR) | 1.03 | 0.88 |
| MACD | 0.15 | 0.05 |
| Stochastic Oscillator | 84.65 | 18.56 |
Wheels Up Experience Inc is a provider of on-demand private aviation. The company offers a private aviation solution with a large and diverse aircraft fleet, delivered through a mix of charter solutions and its membership program that utilizes its controlled aircraft fleet and a network of safety-vetted charter operators. Through its partnership firm, it provides members and customers with an offering across private and premium commercial travel. It generates the majority of its revenue from member and customer flights through its membership program and charter solutions, as well as from membership fees and other activities and services, including group charter flights, cargo flights, and special missions. Geographically, the company generates maximum revenue from the United States.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.